Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 2Phase 3 2Phase 1 2Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Hepatocellular 1Anemia 1

Interventions

Cisplatin 187Carboplatin 182Paclitaxel 177Docetaxel 145Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 82Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 48Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Has results × Pharmacogenomic Testing × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01015833 2022-08-04

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

National Cancer Institute (NCI)

Phase 3 Completed
356 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡